Synergy between L-DOPA and a novel positive allosteric modulator of metabotropic glutamate receptor 4: implications for Parkinson's disease treatment and dyskinesia.

No abstract is available for this paper.

• Publication year

  2013

• Venue

  Neuropharmacology

• Publication date

  2013-03-01

• Fields of study

  Medicine, Chemistry

• Identifiers
  DOI 10.1016/j.neuropharm.2012.03.022PMID 22491024
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• The Metabotropic Glutamate Receptor 4-Positive Allosteric Modulator VU0364770 Produces Efficacy Alone and in Combination with l-DOPA or an Adenosine 2A Antagonist in Preclinical Rodent Models of Parkinson's Disease

  2012cited by this paper
• The Significance of Continuous Dopaminergic Stimulation in the Treatment of Parkinson’s Disease

  2012cited by this paper
• Glutamatergic mechanisms in the dyskinesias induced by pharmacological dopamine replacement and deep brain stimulation for the treatment of Parkinson's disease.

  2012cited by this paper
• Inhibition of Striatal Soluble Guanylyl Cyclase-cGMP Signaling Reverses Basal Ganglia Dysfunction and Akinesia in Experimental Parkinsonism

  2011cited by this paper
• Progress in the Medicinal Chemistry of Group III Metabotropic Glutamate Receptors

  2011cited by this paper
• Discovery, synthesis, and structure-activity relationship development of a series of N-4-(2,5-dioxopyrrolidin-1-yl)phenylpicolinamides (VU0400195, ML182): characterization of a novel positive allosteric modulator of the metabotropic glutamate receptor 4 (mGlu(4)) with oral efficacy in an antiparkins

  2011cited by this paper
• Integrated Synthetic, Pharmacological, and Computational Investigation of cis‐2‐(3,5‐Dichlorophenylcarbamoyl)cyclohexanecarboxylic Acid Enantiomers As Positive Allosteric Modulators of Metabotropic Glutamate Receptor Subtype 4

  2011cited by this paper
• An orally bioavailable positive allosteric modulator of the mGlu4 receptor with efficacy in an animal model of motor dysfunction.

  2010cited by this paper
• Levodopa-induced dyskinesias in patients with Parkinson's disease: filling the bench-to-bedside gap.

  2010cited by this paper
• Deep brain stimulation mechanisms: beyond the concept of local functional inhibition

  2010cited by this paper
• Metabotropic glutamate receptor 4 novel agonist LSP1-2111 with anxiolytic, but not antidepressant-like activity, mediated by serotonergic and GABAergic systems.

  2010cited by this paper
• Therapeutic potential of targeting group III metabotropic glutamate receptors in the treatment of Parkinson's disease

  2010cited by this paper
• Discovery of a potent, selective and in vivo active mGluR4 positive allosteric modulator

  2010cited by this paper
• Reduction of l-DOPA-Induced Dyskinesia by the Selective Metabotropic Glutamate Receptor 5 Antagonist 3-[(2-Methyl-1,3-thiazol-4-yl)ethynyl]pyridine in the 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine-Lesioned Macaque Model of Parkinson's Disease

  2010cited by this paper
• Effect of the metabotropic glutamate receptor type 5 antagonists MPEP and MTEP in parkinsonian monkeys.

  2010cited by this paper
• Effects of GPi and STN inactivation on physiological, motor, cognitive and motivational processes in animal models of Parkinson's disease.

  2010cited by this paper
• Metabotropic glutamate receptors: physiology, pharmacology, and disease.

  2010cited by this paper
• Plastic effects of L-DOPA treatment in the basal ganglia and their relevance to the development of dyskinesia.

  2009cited by this paper
• Metabotropic glutamate receptor subtype 4 selectively modulates both glutamate and GABA transmission in the striatum: implications for Parkinson’s disease treatment

  2009cited by this paper
• Synthesis and SAR of a novel positive allosteric modulator (PAM) of the metabotropic glutamate receptor 4 (mGluR4).

  2009cited by this paper
• Electrophysiological and behavioral evidence that modulation of metabotropic glutamate receptor 4 with a new agonist reverses experimental parkinsonism

  2009cited by this paper
• Metabotropic glutamate mGluR5 receptor blockade opposes abnormal involuntary movements and the increases in glutamic acid decarboxylase mRNA levels induced by l-DOPA in striatal neurons of 6-hydroxydopamine-lesioned rats.

  2009cited by this paper
• Allosteric modulators of GPCRs: a novel approach for the treatment of CNS disorders

  2009cited by this paper
• Deep brain stimulation in neurological diseases and experimental models: from molecule to complex behavior.

  2009cited by this paper
• Molecular mechanisms underlying levodopa‐induced dyskinesia

  2008cited by this paper
• Preventing and controlling dyskinesia in Parkinson's disease—A view of current knowledge and future opportunities

  2008cited by this paper
• Molecular mechanisms of L-DOPA-induced dyskinesia

  2008cited by this paper
• Discovery, Characterization, and Antiparkinsonian Effect of Novel Positive Allosteric Modulators of Metabotropic Glutamate Receptor 4

  2008cited by this paper
• Antagonism of metabotropic glutamate receptor type 5 attenuates l‐DOPA‐induced dyskinesia and its molecular and neurochemical correlates in a rat model of Parkinson’s disease

  2007cited by this paper
• High-Frequency Stimulation of the Subthalamic Nucleus Potentiates l-DOPA-Induced Neurochemical Changes in the Striatum in a Rat Model of Parkinson's Disease

  2007cited by this paper
• Chronic high‐frequency stimulation of the subthalamic nucleus and L‐DOPA treatment in experimental parkinsonism: effects on motor behaviour and striatal glutamate transmission

  2006cited by this paper
• Improved Bioavailability of the mGlu2/3 Receptor Agonist LY354740 Using a Prodrug Strategy: In Vivo Pharmacology of LY544344

  2006cited by this paper
• Metabotropic glutamate receptors in the basal ganglia motor circuit

  2005cited by this paper
• Group III Metabotropic Glutamate-Receptor-Mediated Modulation of Excitatory Transmission in Rodent Substantia Nigra Pars Compacta Dopamine Neurons

  2005cited by this paper
• Subthalamic nucleus lesion reverses motor abnormalities and striatal glutamatergic overactivity in experimental parkinsonism.

  2005cited by this paper
• Metabotropic glutamate receptors and striatal synaptic plasticity: implications for neurological diseases.

  2004cited by this paper
• Therapeutic doses of L-dopa reverse hypersensitivity of corticostriatal D2-dopamine receptors and glutamatergic overactivity in experimental parkinsonism.

  2004cited by this paper
• Lesion therapy for Parkinson's disease and other movement disorders: Update and controversies

  2004cited by this paper
• Loss of bidirectional striatal synaptic plasticity in L-DOPA–induced dyskinesia

  2003cited by this paper
• Group III Metabotropic Glutamate Receptor-Mediated Modulation of the Striatopallidal Synapse

  2003cited by this paper
• Allosteric modulation of group III metabotropic glutamate receptor 4: A potential approach to Parkinson's disease treatment

  2003cited by this paper
• Changes in metabotropic glutamate receptor 1-8 gene expression in the rodent basal ganglia motor loop following lesion of the nigrostriatal tract.

  2002cited by this paper
• L-DOPA-induced dyskinesia in the intrastriatal 6-hydroxydopamine model of parkinson's disease: relation to motor and cellular parameters of nigrostriatal function.

  2002cited by this paper
• Pharmacological validation of behavioural measures of akinesia and dyskinesia in a rat model of Parkinson's disease

  2002cited by this paper
• High-Frequency Stimulation of the Subthalamic Nucleus Selectively Reverses Dopamine Denervation-Induced Cellular Defects in the Output Structures of the Basal Ganglia in the Rat

  2002cited by this paper
• Experimental Parkinsonism Alters Endocannabinoid Degradation: Implications for Striatal Glutamatergic Transmission

  2002cited by this paper
• Distribution and synaptic localisation of the metabotropic glutamate receptor 4 (mGluR4) in the rodent CNS.

  2002cited by this paper
• Frequency of levodopa‐related dyskinesias and motor fluctuations as estimated from the cumulative literature

  2001cited by this paper
• Cortical Slow Oscillatory Activity Is Reflected in the Membrane Potential and Spike Trains of Striatal Neurons in Rats with Chronic Nigrostriatal Lesions

  2001cited by this paper
• In vivo extracellular recording of striatal neurons in the awake rat following unilateral 6-hydroxydopamine lesions.

  2001cited by this paper
• Pathophysiology of the basal ganglia in Parkinson's disease.

  2000cited by this paper
• Immunohistochemical localization of subtype 4a metabotropic glutamate receptors in the rat and mouse basal ganglia

  1999cited by this paper
• Re-evaluation of the functional anatomy of the basal ganglia in normal and Parkinsonian states.

  1997cited by this paper
• Activation of group III metabotropic glutamate receptors depresses glutamatergic transmission at corticostriatal synapse.

  1997cited by this paper
• Functional and pathophysiological models of the basal ganglia.

  1996cited by this paper
• Unilateral 6-hydroxydopamine lesions of meso-striatal dopamine neurons and their physiological sequelae.

  1996cited by this paper
• [3H]‐L‐2‐amino‐4‐phosphonobutyrate labels a metabotropic glutamate receptor, mGluR4a

  1995cited by this paper
• Electrophysiology of dopamine-denervated striatal neurons. Implications for Parkinson's disease.

  1993cited by this paper
• Levodopa‐induced dyskinesias in Parkinson's disease: Clinical and pharmacological classification

  1992cited by this paper
• Membrane properties and synaptic responses of rat striatal neurones in vitro.

  1991cited by this paper
• Neurotransmitters and neuromodulators in the basal ganglia.

  1990cited by this paper
• The functional anatomy of basal ganglia disorders.

  1989cited by this paper
• Effects of dopamine depletion on the spontaneous activity of type I striatal neurons: Relation to local dopamine concentration and motor behavior

  1987cited by this paper
• Passive electrical membrane properties of rat neostriatal neurons in an in vitro slice preparation.

  1984cited by this paper
• The Rat Brain in Stereotaxic Coordinates

  1983cited by this paper
• The rat forebrain in stereotaxic coordinates

  1959cited by this paper
• Synaptopathies: Dysfunction of Synaptic Function Synaptic Dysfunction in Parkinson's Disease

  year unknowncited by this paper

• Update on mGlu4 modulator patents: 2017 to present

  2025cites this paper
• Targeting metabotropic glutamate receptors for symptomatic and disease-modifying treatment in Parkinson’s disease

  2025cites this paper
• Metabotropic glutamate receptors in GtoPdb v.2025.3

  2025cites this paper
• G protein-coupled receptors: A golden key to the treasure-trove of neurodegenerative diseases.

  2025cites this paper
• Advances and Insights in Positron Emission Tomography Tracers for Metabotropic Glutamate Receptor 4 Imaging.

  2024cites this paper
• Elucidating the molecular logic of a metabotropic glutamate receptor heterodimer

  2024cites this paper
• mGlu4R, mGlu7R, and mGlu8R allosteric modulation for treating acute and chronic neurodegenerative disorders

  2024cites this paper
• Ion Channels and Metal Ions in Parkinson's Disease: Historical Perspective to the Current Scenario.

  2024cites this paper
• Metabotropic Glutamate Receptor 4 (mGlu4) Positive Allosteric Modulators Lack Efficacy in Rat and Marmoset Models of L-DOPA-Induced Dyskinesia

  2024cites this paper
• Targeting mGluR group III for the treatment of neurodegenerative diseases.

  2023cites this paper
• Metabotropic glutamate receptors in GtoPdb v.2023.1

  2023cites this paper
• Foliglurax, a positive allosteric modulator of the metabotrophic glutamate receptor 4, protects dopaminergic neurons in MPTP-lesioned male mice.

  2023cites this paper
• Metabotropic glutamate receptors in Parkinson's disease.

  2023cites this paper
• Glutamate modulation for the treatment of levodopa induced dyskinesia: a brief review of the drugs tested in the clinic.

  2022cites this paper
• Allosteric Modulators of Metabotropic Glutamate Receptors as Novel Therapeutics for Neuropsychiatric Disease

  2022cites this paper
• Non-dopaminergic approaches to the treatment of motor complications in Parkinson's disease.

  2022cites this paper
• Classic and Modern Approaches to Investigating Interactions Between Dopamine Systems and Metabotropic Glutamate Receptors

  2021cites this paper
• Haloperidol‐induced catalepsy as an animal model for parkinsonism: A systematic review of experimental studies

  2021cites this paper
• New 1,2,4-oxadiazole derivatives with positive mGlu4 receptor modulation activity and antipsychotic-like properties

  2021cites this paper
• Discovery and optimization of a novel CNS penetrant series of mGlu4 PAMs based on a 1,4-thiazepane core with in vivo efficacy in a preclinical Parkinsonian model.

  2021cites this paper
• Metabotropic glutamate receptors in GtoPdb v.2021.3

  2021cites this paper
• Allosteric modulators targeting GPCRs

  2020cites this paper
• Antiparkinsonian Effects of a Metabotropic Glutamate Receptor 4 Agonist in MPTP-Treated Marmosets

  2020cites this paper
• A case study of foliglurax, the first clinical mGluR4 PAM for symptomatic treatment of Parkinson’s disease: translational gaps or a failing industry innovation model?

  2020cites this paper
• Antiparkinsonian effects of a metabotropic glutamate receptor 4 agonist in 1 MPTP-treated marmosets 2

  2020cites this paper
• Synthesis and Characterization of Fluorine-18 labeled N-(4-Chloro-3-((fluoromethyl-d2)thio)phenyl)picolinamide for Imaging of mGluR4 in Brain.

  2020cites this paper
• G protein-coupled receptors in neurodegenerative diseases

  2020cites this paper
• Metabotropic glutamate receptors (version 2019.4) in the IUPHAR/BPS Guide to Pharmacology Database

  2019cites this paper
• Characterisation of metabotropic glutamate receptor 4 as a therapeutic target in Parkinson's disease

  2019cites this paper
• Roles of Glutamate Receptors in Parkinson’s Disease

  2019cites this paper
• Family C G-Protein-Coupled Receptors in Alzheimer’s Disease and Therapeutic Implications

  2019cites this paper
• The discovery of VU0652957 (VU2957, Valiglurax): SAR and DMPK challenges en route to an mGlu4 PAM development candidate.

  2019cites this paper
• Imaging metabotropic glutamate receptor system: Application of positron emission tomography technology in drug development

  2019cites this paper
• Receptor Ligands as Helping Hands to L-DOPA in the Treatment of Parkinson’s Disease

  2019influential citation
• The Modulation of Pain by Metabotropic Glutamate Receptors 7 and 8 in the Dorsal Striatum

  2019cites this paper
• Discovery of VU2957 (Valiglurax): An mGlu4 Positive Allosteric Modulator Evaluated as a Preclinical Candidate for the Treatment of Parkinson's Disease.

  2018cites this paper
• Glutamatergic mechanisms in l-DOPA-induced dyskinesia and therapeutic implications

  2018cites this paper
• Opportunities and challenges in drug discovery targeting metabotropic glutamate receptor 4

  2018cites this paper
• mGlu receptors in the treatment of Parkinson's disease and L-DOPA-induced dyskinesia.

  2018cites this paper
• mGlu4 allosteric modulation for treating Parkinson's disease

  2018cites this paper
• An mGlu4‐Positive Allosteric Modulator Alleviates Parkinsonism in Primates

  2018cites this paper
• Discovery, Structure-Activity Relationship, and Biological Characterization of a Novel Series of 6-((1 H-Pyrazolo[4,3- b]pyridin-3-yl)amino)-benzo[ d]isothiazole-3-carboxamides as Positive Allosteric Modulators of the Metabotropic Glutamate Receptor 4 (mGlu4).

  2018cites this paper
• Drugs to Tune Up Glutamatergic Systems: Modulators of Glutamate Metabotropic Receptors

  2018cites this paper
• Control of Motor Function by Adenosine A2A Receptors in Parkinson's and Huntington's Disease

  2017cites this paper
• 2.11 – Allosteric Modulators

  2017cites this paper
• The impact of metabotropic glutamate receptors into active neurodegenerative processes: A “dark side” in the development of new symptomatic treatments for neurologic and psychiatric disorders

  2017influential citation
• Recent advances in drug discovery of GPCR allosteric modulators for neurodegenerative disorders

  2017cites this paper
• Metabotropic glutamate receptors as therapeutic targets in Parkinson's disease: An update from the last 5 years of research

  2017influential citation
• Metabotropic glutamate receptors and neurodegenerative diseases.

  2017cites this paper
• Discovery, Structure-Activity Relationship, and Antiparkinsonian Effect of a Potent and Brain-Penetrant Chemical Series of Positive Allosteric Modulators of Metabotropic Glutamate Receptor 4.

  2017cites this paper
• Targeting metabotropic glutamate receptors for novel treatments of schizophrenia

  2017influential citation
• Current Nondopaminergic Therapeutic Options for Motor Symptoms of Parkinson's Disease

  2017cites this paper
• mGlu5 Receptors in Parkinson’s Disease and MPTP-Lesioned Monkeys: Behavior and Brain Molecular Correlates

  2017cites this paper
• Metabotropic Glutamate Receptors and Parkinson’s Disease: Basic and Preclinical Neuroscience

  2017cites this paper
• Recent advances in the medicinal chemistry of group II and group III mGlu receptors.

  2017cites this paper
• Old and new challenges in Parkinson's disease therapeutics

  2017cites this paper
• Selective and interactive effects of D2 receptor antagonism and positive allosteric mGluR4 modulation on waiting impulsivity

  2017cites this paper
• Discovery and characterization of a novel series of N-phenylsulfonyl-1H-pyrrole picolinamides as positive allosteric modulators of the metabotropic glutamate receptor 4 (mGlu4).

  2016cites this paper
• Practical Strategies and Concepts in GPCR Allosteric Modulator Discovery: Recent Advances with Metabotropic Glutamate Receptors.

  2016cites this paper
• Metabotropic Glutamate Receptors in Central Nervous System Diseases.

  2016cites this paper
• Synthesis and evaluation of N-(methylthiophenyl)picolinamide derivatives as PET radioligands for metabotropic glutamate receptor subtype 4.

  2016cites this paper
• mGluR4-containing corticostriatal terminals: synaptic interactions with direct and indirect pathway neurons in mice

  2016cites this paper
• The Metabotropic Glutamate Receptor 4 Positive Allosteric Modulator ADX88178 Inhibits Inflammatory Responses in Primary Microglia

  2016cites this paper
• Development and Antiparkinsonian Activity of VU0418506, a Selective Positive Allosteric Modulator of Metabotropic Glutamate Receptor 4 Homomers without Activity at mGlu2/4 Heteromers.

  2016cites this paper
• Pharmacological stimulation of metabotropic glutamate receptor type 4 in a rat model of Parkinson's disease and L-DOPA-induced dyskinesia: Comparison between a positive allosteric modulator and an orthosteric agonist.

  2015influential citation
• Discovery and Biochemical Evaluation of Chemical Probes for the Study of Jumonji-C Domain Containing Histone Demethylases and Antibiotic Resistance Machinery in MRSA

  2015cites this paper
• Pathophysiology of L-dopa-induced motor and non-motor complications in Parkinson's disease.

  2015cites this paper
• Adenosine A2A Receptor Antagonists in L-DOPA-Induced Motor Fluctuations

  2015cites this paper
• Rôle de Narp dans le développement des dyskinésies induites par la L-DOPA

  2015cites this paper
• Re-exploring the N-phenylpicolinamide derivatives to develop mGlu4 ligands with improved affinity and in vitro microsomal stability.

  2015cites this paper
• Targeting metabotropic glutamate receptors (mGluRs) in Parkinson's disease.

  2015cites this paper
• Group III Metabotropic Glutamate Receptors: Pharmacology, Physiology and Therapeutic Potential

  2014cites this paper
• The antipsychotic-like effects in rodents of the positive allosteric modulator Lu AF21934 involve 5-HT1A receptor signaling: mechanistic studies

  2014cites this paper
• Chemical biology of mGlu4 receptor activation: dogmas, challenges, strategies and opportunities.

  2014cites this paper
• Microglial Biology in Neuroinflammatory Disease: Pharmaco-industrial Approach to Target Validation

  2014cites this paper
• Investigating group III metabotropic glutamate receptors as novel therapeutic targets in Parkinson's disease and Levodopa-induced dyskinesia

  2014cites this paper
• Selective Actions of Novel Allosteric Modulators Reveal Functional Heteromers of Metabotropic Glutamate Receptors in the CNS

  2014cites this paper
• Multifunctional approach of L-Dopa induced dyskinesia pathophysiology in Parkinson’s disease : from the striatum to the whole brain

  2014cites this paper
• Therapeutic potential of targeting glutamate receptors in Parkinson’s disease

  2014cites this paper
• Neuroprotective and symptomatic effects of targeting group III mGlu receptors in neurodegenerative disease

  2014influential citation
• Lu AF21934, a positive allosteric modulator of mGlu4 receptors, reduces the harmaline-induced hyperactivity but not tremor in rats.

  2014influential citation
• Progress toward advanced understanding of metabotropic glutamate receptors: structure, signaling and therapeutic indications.

  2014cites this paper
• Glutamatergic pathways as a target for the treatment of dyskinesias in Parkinson's disease.

  2014cites this paper
• Development of allosteric modulators of GPCRs for treatment of CNS disorders.

  2014cites this paper
• Pharmacological Treatments Inhibiting Levodopa-Induced Dyskinesias in MPTP-Lesioned Monkeys: Brain Glutamate Biochemical Correlates

  2014cites this paper
• Inhibitory actions of mGlu_4 receptor ligands on cocaine-, but not nicotine-, induced sensitizing and conditioning locomotor responses in rats

  2014cites this paper
• Opportunities and challenges in the discovery of allosteric modulators of GPCRs for treating CNS disorders

  2014cites this paper
• Distinct effects of mGlu4 receptor positive allosteric modulators at corticostriatal vs. striatopallidal synapses may differentially contribute to their antiparkinsonian action.

  2014influential citation
• Identification of Positive Allosteric Modulators VU0155094 (ML397) and VU0422288 (ML396) Reveals New Insights into the Biology of Metabotropic Glutamate Receptor 7

  2014cites this paper
• Qualification of LSP1-2111 as a Brain Penetrant Group III Metabotropic Glutamate Receptor Orthosteric Agonist.

  2014cites this paper
• Pathophysiology of L-Dopa Induced Dyskinesia — Changes in D1/D3 Receptors and Their Signaling Pathway

  2014cites this paper
• The antipsychotic‐like effects of positive allosteric modulators of metabotropic glutamate mGlu4 receptors in rodents

  2013cites this paper
• Early life stress causes refractoriness to haloperidol-induced catalepsy

  2013cites this paper
• Microsoft Word-63000922-file00

  2013cites this paper
• Early Life Stress Causes Refractoriness to Haloperidol-Induced Catalepsy

  2013cites this paper
• Anxiolytic- but not antidepressant-like activity of Lu AF21934, a novel, selective positive allosteric modulator of the mGlu₄ receptor.

  2013cites this paper
• Author ' s personal copy Invited review Group III and subtype 4 metabotropic glutamate receptor agonists : Discovery and pathophysiological applications in Parkinson ’ s disease

  2013influential citation
• Modulation of basal ganglia function by metabotropic glutamate receptors

  2013influential citation
• Group III and subtype 4 metabotropic glutamate receptor agonists: discovery and pathophysiological applications in Parkinson's disease.

  2013cites this paper
• Pharmacology of metabotropic glutamate receptor allosteric modulators: structural basis and therapeutic potential for CNS disorders.

  2013cites this paper